Europska Unija - hrvatski - EMA (European Medicines Agency)

mundipharma corporation (ireland) limited - pegfilgrastim - neutropenija - Иммуностимуляторы, - za smanjenje trajanja нейтропении i frekvencije фебрильной нейтропении protiv kemoterapije.

Crna Gora - hrvatski - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek pharma" doo podgorica - fluorouracil - rastvor za injekciju/infuziju - 50mg/ml

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - molimo pogledajte dokument s informacijama o proizvodu.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidno slikanje - dijagnostički radiofarmaceutici - ovaj je lijek samo za dijagnostičku uporabu. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresivi - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psorijatični arthritiscosentyx, odvojeno ili u kombinaciji sa metotreksatom (mtx), propisan za liječenje aktivnog psorijatični artritis kod odraslih pacijenata, kada je odgovor na prethodna bolest дорабатывая anti-reumatskih lijekovi (dmards) terapija je bila neadekvatna.. Аксиальный спондилоартрит (axspa)ankilozantni спондилоартрит (kao, радиографические osi спондилоартрит)cosentyx indiciran za liječenje aktivnog анкилозирующего спондилита kod odraslih, koji su adekvatno odgovorili na standardnu terapiju. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

glaxosmithkline trading services limited - Занамивир - gripa, ljudska - antivirusni lijekovi za sustavnu uporabu - dectova indiciran za liječenje složene i potencijalno opasne gripe a ili b virusna infekcija kod odraslih i pedijatrijska bolesnika (u dobi ≥6 mjeseci), kada:bolesno virus gripe može biti otporan na противогриппозных lijekova, drugih, nego занамивир, i/ili antivirusnih lijekova za liječenje gripe, uključujući i ингаляционный занамивир, nisu pogodni za pojedinog pacijenta.. dectova mora se koristiti u skladu sa službenim vodstvom.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - tumori prostate, Кастраци-uporan - terapeutski radiofarmaceutski pripravci - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

amicus therapeutics europe limited - migalastat hydrochloride - fabry-ovu bolest - migalastat - galafold je naznačeno za dugoročno liječenje odraslih i adolescenata u dobi od 16 godina i stariji sa dijagnoze bolesti fabry (α-galaktozidaza manjak) i koji imaju pogodan mutacija.

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - dijabetes mellitus, tip 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama).

Europska Unija - hrvatski - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemija, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.